Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Interest & Investment Income (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Interest & Investment Income for 13 consecutive years, with $5.8 million as the latest value for Q1 2026.

  • For Q1 2026, Interest & Investment Income fell 41.2% year-over-year to $5.8 million; the TTM value through Mar 2026 reached $29.6 million, down 32.73%, while the annual FY2025 figure was $33.7 million, 17.67% down from the prior year.
  • Interest & Investment Income hit $5.8 million in Q1 2026 for Viking Therapeutics, down from $7.0 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $11.8 million in Q2 2024 and bottomed at $154000.0 in Q1 2022.
  • Average Interest & Investment Income over 5 years is $5.7 million, with a median of $5.8 million recorded in 2026.
  • Year-over-year, Interest & Investment Income surged 1697.23% in 2023 and then crashed 41.2% in 2026.
  • Viking Therapeutics' Interest & Investment Income stood at $732000.0 in 2022, then skyrocketed by 542.9% to $4.7 million in 2023, then soared by 130.43% to $10.8 million in 2024, then crashed by 35.13% to $7.0 million in 2025, then dropped by 17.56% to $5.8 million in 2026.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $5.8 million, $7.0 million, and $7.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.